Nucleic acid therapeutics need effective delivery to avoid degradation and poor uptake. Though chemical mods boost mRNA stability, intracellular delivery and endosomal escape remain key hurdles—polymer-based vectors condense/protect mRNA for cytoplasmic release, enabling optimal protein expression.
Creative Biolabs offers custom Polymer-based Vector Development via advanced engineering. We tailor solutions to maximize transfection, minimize toxicity, overcome endosomal entrapment and non-specific biodistribution, and accelerate your gene therapy pipeline.
Discover How We Can Help - Request a ConsultationCreative Biolabs offers tailored services for both fundamental polymer vector types, ensuring the selection of the most suitable carrier for your therapeutic objective.
![Chemical structures of poly(L-lysine), poly(β-amino ester) (PBAE), poly[(2-dimethylamino) ethyl methacrylate] (pDMAEMA), poly(lactic-co-glycolic acid) (PLGA), chitosan, and poly(amino-co-ester) (PACE). (OA Literature)](static/img/1-3-2-polymer-based-vector-development-services.jpg)
Fig.1 The chemical structure of cationic polymers commonly used for nucleic acid delivery.1
Polyplexes are formed based on the fundamental electrostatic interaction between the positively charged polycation and the negatively charged mRNA backbone. Our service optimizes:
Micelleplexes are sophisticated, self-assembled structures generated from block copolymers. These structures offer key advantages in complex biological environments:
Our robust, systematic workflow ensures the development of polymer vectors precisely tailored to your specific mRNA therapeutic goals.
| Step | Activity Involved |
|---|---|
| Project Scoping & Polymer Selection | Required Starting Materials: Target cell line or tissue; mRNA sequence and modification status; Desired route of administration (e.g., systemic, localized). |
| Polymer Synthesis & Characterization | Bottom-up synthesis of novel cationic polymers (including functional group modifications for targeted delivery), followed by physicochemical characterization. |
| Vector (Polyplex/Micelleplex) Formulation | Complexation of the synthetic polymer with the mRNA payload under various ratios; Optimization of formulation buffer and physical parameters (e.g., mixing method). |
| In Vitro Efficacy & Toxicity Assessment | Testing vector formulations in target cell models to measure transfection efficiency (reporter gene expression) and perform detailed cytotoxicity assays. |
| Stability and Scalability Evaluation | Assessing formulation stability under storage conditions; Developing protocols for scaled-up synthesis and formulation suitable for large-batch production. |
Creative Biolabs' Polymer-based Vector Development service is an expert-level solution for biologists and biopharma developers seeking to maximize therapeutic impact. We offer highly customized services that circumvent the critical biological and manufacturing hurdles of non-viral delivery.
Custom Vector Blueprinting
Tailor vector architectures by optimizing polymer chemistry (e.g., next-gen PACE, PBAE) to your mRNA payload, target cell, and administration route, ensuring the most efficient delivery system.
Unrivaled Efficacy & Payload Release
Use our engineering expertise to optimize the "Proton Sponge Effect," boosting endosomal escape and increasing intact mRNA release into the cytoplasm for effective protein translation.
Safety by Design
Synthesize next-gen biodegradable polymers with cleavable bonds, eliminating traditional cationic carrier risks via minimal systemic toxicity and rapid in vivo clearance.
Scalable, GMP-Ready Production
Enable seamless R&D-to-clinical transition with "bottom-up" polymer synthesis protocols—designed for industrial scale, ensuring reproducible, regulatory-compliant batches.
Comprehensive Formulation Services
Deliver optimized Polyplex/Micelleplex protocols, with precise control over nanoparticle size, charge, and stability to maximize therapeutic effect.
A: We prioritize next-generation polymers like PBAE and PACE, which are chemically designed with cleavable ester bonds. These biodegradable structures break down in vivo, significantly reducing the long-term vector retention and the associated high cytotoxicity seen with non-degradable, first-generation polycations. Contact us to review the comprehensive safety data.
A: Absolutely. The versatility of polymer chemistry is a core advantage. We can functionalize the polymer surface during synthesis, allowing for the covalent attachment of targeting ligands (e.g., peptides, antibodies) to direct the vector to specific receptors on desired cell types, maximizing localized efficacy.
A: Both are excellent non-viral systems. While LNPs are established, polymer systems (Polyplexes/Micelleplexes) offer superior chemical flexibility and can often be synthesized using more robust, scalable methods. For applications requiring specific charge-based targeting or highly tunable release kinetics, polymers may be preferred. Let's discuss your specific application needs to find the optimal platform.
A: Our cationic polymers are designed to function via the "Proton Sponge Effect." Once internalized via endocytosis, the polymer's primary and tertiary amines buffer the endosome, leading to osmotic swelling and rupture of the endosome membrane, successfully releasing the intact mRNA into the cytoplasm to start translation.
Creative Biolabs is your end-to-end partner for overcoming non-viral mRNA delivery challenges. We specialize in engineering high-performance Polyplex and Micelleplex vectors that combine advanced safety profiles with superior gene transfection efficiency, ensuring your therapeutic project scales successfully from concept to clinic.
Contact Our Team for More Information and to Discuss Your Project| Cat. No | Product Name | Promoter |
|---|---|---|
| CAT#: GTVCR-WQ001MR | IVTScrip™ pT7-mRNA-EGFP Vector | T7 |
| CAT#: GTVCR-WQ002MR | IVTScrip™ pT7-VEE-mRNA-EGFP Vector | T7 |
| CAT#: GTVCR-WQ003MR | IVTScrip™ pT7-VEE-mRNA-FLuc Vector | T7 |
| CAT#: GTVCR-WQ87MR | IVTScrip™ pT7-VEE-mRNA-Anti-SELP, 42-89-glycoprotein Vector | T7 |
| Cat. No | Product Name | Type |
|---|---|---|
| CAT#: GTTS-WQ001MR) | IVTScrip™ mRNA-EGFP (Cap 1, 30 nt-poly(A)) | Reporter Gene |
| CAT#: GTTS-WK18036MR | IVTScrip™ mRNA-Human AIMP2, (Cap 1, Pseudo-UTP, 120 nt-poly(A)) | Enzyme mRNA |
| (CAT#: GTTS-WQ004MR) | IVTScrip™ mRNA-Fluc (Cap 1, 30 nt-poly(A)) | Reporter Gene |
| (CAT#: GTTS-WQ009MR) | IVTScrip™ mRNA-β gal (Cap 1, 30 nt-poly(A)) | Reporter Gene |
Reference
